Format

Send to

Choose Destination
J Clin Psychiatry. 2017 Jun;78(6):e656-e667. doi: 10.4088/JCP.16r11113.

S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research.

Author information

1
Department of Psychiatry, University of Pennsylvania School of Medicine, 10th Floor Gates Bldg, 3400 Spruce St, Philadelphia, PA 19104. anup@mail.med.upenn.edu.
2
Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
3
Department of Psychiatry, New York Medical College, Vahalla, New York, USA.
4
Institute of Metabolic Disease, Baylor Research Institute, Dallas, Texas, USA.
5
Department of Psychiatry, Michigan State University, East Lansing, Michigan, USA.
6
Butler Hospital, Brown Department of Psychiatry and Human Behavior, Providence, Rhode Island, USA.
7
Department of Psychiatry, UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, USA.
8
Columbia University Medical Center, New York, New York, USA.
9
Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Abstract

OBJECTIVE:

A systematic review on S-adenosylmethionine (SAMe) for treatment of neuropsychiatric conditions and comorbid medical conditions.

DATA SOURCES:

Searches were conducted in PubMed, EMBASE, PsycINFO, Cochrane Library, CINAHL, and Google Scholar databases between July 15, 2015, and September 28, 2016, by combining search terms for SAMe (s-adenosyl methionine or s-adenosyl-l-methionine) with terms for relevant disease states (major depressive disorder, MDD, depression, perinatal depression, human immunodeficiency virus, HIV, Parkinson's, Alzheimer's, dementia, anxiety, schizophrenia, psychotic, 22q11.2, substance abuse, fibromyalgia, osteoarthritis, hepatitis, or cirrhosis). Additional studies were identified from prior literature. Ongoing clinical trials were identified through clinical trial registries.

STUDY SELECTION:

Of the 174 records retrieved, 21 were excluded, as they were not original investigations. An additional 21 records were excluded for falling outside the scope of this review. Of the 132 studies included in this review, 115 were clinical trials and 17 were preclinical studies.

DATA EXTRACTION:

A wide range of studies was included in this review to capture information that would be of interest to psychiatrists in clinical practice.

RESULTS:

This review of SAMe in the treatment of major depressive disorder found promising but limited evidence of efficacy and safety to support its use as a monotherapy and as an augmentation for other antidepressants. Additionally, preliminary evidence suggests that SAMe may ameliorate symptoms in certain neurocognitive, substance use, and psychotic disorders and comorbid medical conditions.

CONCLUSIONS:

S-adenosylmethionine holds promise as a treatment for multiple neuropsychiatric conditions, but the body of evidence has limitations. The encouraging findings support further study of SAMe in both psychiatric and comorbid medical illnesses.

PMID:
28682528
PMCID:
PMC5501081
DOI:
10.4088/JCP.16r11113
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Physicians Postgraduate Press, Inc. Icon for PubMed Central
Loading ...
Support Center